Literature DB >> 30705432

Glioblastoma is 'hot' for personalized vaccines.

Maria Giuseppina Baratta1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30705432     DOI： 10.1038/s41568-019-0118-8

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  5 in total

Review 1.  Immunotherapy for Neuro-oncology.

Authors:  Nazanin K Majd; Pushan R Dasgupta; John F de Groot
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Knockdown of T Cell Immunoglobulin and Mucin 1 (Tim-1) Suppresses Glioma Progression Through Inhibition of the Cytokine-PI3K/AKT Pathway.

Authors:  Peng Zhou; Maoxing Fei; Yanling Han; Mengliang Zhou; Handong Wang
Journal:  Onco Targets Ther       Date:  2020-08-04       Impact factor: 4.147

3.  Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells.

Authors:  Sophie A Dusoswa; Sophie K Horrevorts; Martino Ambrosini; Hakan Kalay; Nanne J Paauw; Rienk Nieuwland; Michiel D Pegtel; Tom Würdinger; Yvette Van Kooyk; Juan J Garcia-Vallejo
Journal:  J Extracell Vesicles       Date:  2019-08-09

4.  Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins.

Authors:  Bach-Ngan Nguyen; Florian Tieves; Thomas Rohr; Hilke Wobst; Felix S Schöpf; Jóse D Montoya Solano; Julia Schneider; Janpeter Stock; Andreas Uhde; Thomas Kalthoff; Karl Erich Jaeger; Lutz Schmitt; Christian Schwarz
Journal:  AMB Express       Date:  2021-03-25       Impact factor: 3.298

Review 5.  Nanomedicine-based immunotherapy for central nervous system disorders.

Authors:  Sumaira Hanif; Pir Muhammad; Rose Chesworth; Fawad Ur Rehman; Rong-Jun Qian; Meng Zheng; Bing-Yang Shi
Journal:  Acta Pharmacol Sin       Date:  2020-05-28       Impact factor: 6.150
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.